Biosynex – i-Tracker: High-performance TDM assays for biologics

Therapeutic Drug Monitoring (TDM) of biologics entails measuring drug and anti-drug antibody concentrations, with subsequent possible dose adjustment to ensure optimised dosing for the patient.

With their high-performance and short turnaround time, i-Tracker CLIA kits, in combination with the i-Track random-access analyser, enable the clinician to make therapeutic decisions promptly.

In giving access to rapid treatment adjustments, i-Tracker assays contribute to improve overall clinical outcomes for the patients while minimising the cost of treatment.

• Innovative CLIA technology
• Short turnaround time
• Validated on princeps and biosimilars
• Calibrated against WHO international standards
  

  ---

Interpret dosing information

• Drug levels required to improve clinical outcomes may vary between patients and depend on the desired therapeutic endpoint.
• ​​​​​In patients with undetectable drug levels, anti-drug antibody (ADAb) quantification helps to identify how to improve patient response.
• In patients considered to be good responders with higher drug trough levels, dose escalation may be possible without affecting clinical outcomes.
• In patients with high anti-drug antibody levels, a switch in class may be necessary.
• In patients with low anti-drug antibody levels, the addition of an immunosuppressive drug may improve clinical outcomes.

Ex​​​​​​ample of therapeutic decision algorithm in patients with loss of response:

THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.

Go Back